Goldman SachsGSDON'T BUYOct 09, 2014Stock price when the opinion was issued
As of Jul 21, 2026. Market Open.
Different businesses. LLY is a big play in GLP-1 drugs. How will pills effect the injections business? LLY has done a good job of navigating these new pills. GS enjoys increased stock market and IPO businesses. He prefers LLY, which is tied to a secular growth trend, but GS' good times in capturing revenue in this cycle will end.
Mergers are increasing, and banks like GS makes advisory fees from them. Also, the banks have been rallying since oil slumped, and will benefit further from rising interest rates, which appears will happen later this year. Plus, hyperscalers may need to keep borrowing money to keep competing with each other.
3% drop in the stock is fine for a company that has a highly levered balance sheet. It is obviously best in breed in terms of the banking space. This is a money centered banks, so it is very firmly focused in terms of regulation, bank changes, etc. which means that every time there is a sneeze in the market, the regulators are going to be dealing a lot with banks like this. He prefers US regional banks, which don’t have the same regulatory glare.